Member companies of the Pharmaceutical Research and Manufacturers of America invested an estimated $51.2 billion last year in the research and development of new innovative treatments and cures. The figure represents the majority of all biopharmaceutical R&D spending, both public and private, in the U.S.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
